BUY Lupin Limited — HSBC Securities
byHSBC SecuritiesHorizon: NA (inferred 1 year)22 Sept 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Lupin share price is currently 'overemphasizing' a risk while 'undermining' a positive, HSBC says
NewsCnbc-Tv18·22 Sept · today
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·22 Sept · today
5 advisors have active short-term BUY calls on this stock, with 4 issued in the last 14 days
Advisor consensus · adjacent horizon·22 Sept · today
Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
NewsGoogle News·16 Sept · 5d ago
Lupin Inaugurates Atharv Ability Neuro-Rehabilitation Center in Delhi, Expanding Specialized Care in North India
NewsGoogle News·15 Sept · 6d ago
Nothing found in this tip’s window yet.
Lupin share falls 2%; Citi downgrades to Sell, cuts target price to Rs 2,050
NewsEt-Markets·27 Aug · 4w ago
Lupin share price: Citi downgrades, cuts target; Bernstein sees Kalydeco ruling as key positive
NewsCnbc-Tv18·27 Aug · 4w ago
1 other SEBI-registered advisor has an active long-term SELL call on this stock
Advisor consensus · same horizon·27 Aug · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.